Review of clinical studies of perampanel in adolescent patients.
OBJECTIVE
To assess the clinical trial and real-world data for adjunctive perampanel in adolescents and develop consensus recommendations to guide the use of perampanel in this population in clinical practice.


METHODS
In May 2015, 15 epilepsy experts attended a Consensus Development Meeting to assess the clinical trial data for perampanel, specific to the adolescent age group (12-17 years) and develop consensus treatment recommendations.


CONCLUSIONS
Analysis of the adolescent subgroup data of three pivotal placebo-controlled, double-blind, phase 3 trials investigating perampanel in patients with ongoing focal epileptic seizures despite receiving one to three antiepileptic drugs found that perampanel 4-12 mg was superior to placebo. The tolerability profile of perampanel was generally acceptable. Adolescent patients receiving long-term treatment with perampanel in an open-label extension study maintained improvements in seizure control compared with baseline, with a favorable risk-benefit profile. A phase 2 study showed that perampanel had no clinically important effects on cognitive function, growth, and development.


CONCLUSIONS
Perampanel is a welcome addition to the armamentarium of existing antiepileptic drugs as it represents a new approach in the management of epilepsy, with a novel mechanism of action, and the potential to have a considerable impact on the treatment of adolescents with epilepsy.
Division of Pediatric Neurology Yonsei University Severance Children's Hospital Seoul Korea.
Heung Dong
HD
Kim
Department of Pediatrics Tungs' Taichung Metro Harbor Hospital Taichung Taiwan.
Ching-Shiang
CS
Chi
Department of Paediatric Neurology King Chulalongkorn Memorial Hospital Bangkok Thailand.
Tayard
T
Desudchit
Children's Department Danish Epilepsy Centre Filadelfia Dianalund Denmark.
Marina
M
Nikanorova
Division of Neurology Department of Pediatrics Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand.
Anannit
A
Visudtibhan
Department of Paediatrics Phramongkutklao Hospital Bangkok Thailand.
Charcrin
C
Nabangchang
Department of Paediatrics KK Women's and Children's Hospital Singapore City Singapore.
Derrick W S
DW
Chan
Division of Paediatric Neurology Department of Paediatrics Faculty of Medicine University of Malaya Kuala Lumpur Malaysia.
Choong Yi
CY
Fong
Department of Pediatrics Taipei Veterans General Hospital Taipei Taiwan.
Kai-Ping
KP
Chang
Department of Neurology Taipei Veterans General Hospital Taipei Taiwan.
Shang-Yeong
SY
Kwan
Department of Pediatrics Mother Seton Hospital Camarines Sur Philippines.
Fe De Los
FL
Reyes
Department of Pediatrics College of Medicine Taipei Medical University Taipei Taiwan.
Chao-Ching
CC
Huang
Department of Pediatrics Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand.
Surachai
S
Likasitwattanakul
Department of Pediatrics National Taiwan University Hospital Taipei Taiwan.
Wang-Tso
WT
Lee
Department of Pediatrics The Duchess of Kent Children's Hospital Sandy Bay Hong Kong.
Ada
A
Yung
Eisai Pharmaceuticals India Pvt., Ltd. Mumbai India.
Amitabh
A
Dash
Adolescent; Anticonvulsants; consensus; epilepsy; perampanel; receptors AMPA
Neuropediatrics. 2015 Apr;46(2):110-6
25730374
Epilepsia. 2013 Aug;54(8):1481-9
23663001
Epilepsia. 2011 Jul;52(7):1331-40
21635236
Arch Dis Child. 1970 Feb;45(239):13-23
5440182
Epilepsia. 2013 Jan;54(1):126-34
22905878
Eur J Paediatr Neurol. 2015 Jul;19(4):435-45
25823975
Neurology. 2012 May 1;78(18):1408-15
22517103
Neurology. 2012 Aug 7;79(6):589-96
22843280
Epilepsy Res. 2014 Jul;108(5):986-8
24721197
Brain Behav. 2016 Jun 28;6(9):e00505
27688936
Epilepsia. 2013 Jan;54(1):117-25
22905857
Epilepsia. 2016 Feb;57(2):243-51
26724782
Epilepsy Curr. 2011 Mar;11(2):56-63
21686307